Annexon Biosciences Lands $44,000,000 Series B Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9a44c46e-ee14-47a6-8704-7bd56efcd484
Date
6/23/2016
Company Name
Annexon Biosciences
Mailing Address
280 Utah Avenue South San Francisco, CA 94080 USA
Company Description
Annexon is a California-based healthcare company engaged in the R&D of novel disease-modifying drugs for neurodegenerative disorders.
Website
http://www.annexonbio.com
Transaction Type
Venture Equity
Transaction Amount
$44,000,000
Transaction Round
Series B
Proceeds Purposes
This significant investment in our robust and risk-balanced pipeline further validates Annexon’s novel and elegant scientific approach. Moreover, the funding enables us to enhance and accelerate our biomarker-rich clinical development program in support of new and much-needed therapies for patients with serious neurodegenerative disorders.
M&A Terms
Venture Investor
New Enterprise Associates
Venture Investor
Correlation Ventures
Venture Investor
Novartis Venture Fund
Venture Investor
Clarus Ventures
Venture Investor
Satter Investment Management